Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
GNVC's Cash to Debt is ranked higher than
99% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. GNVC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GNVC' s Cash to Debt Range Over the Past 10 Years
Min: 1.64  Med: 14.83 Max: No Debt
Current: No Debt
Equity to Asset 0.81
GNVC's Equity to Asset is ranked higher than
68% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. GNVC: 0.81 )
Ranked among companies with meaningful Equity to Asset only.
GNVC' s Equity to Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.75 Max: 0.88
Current: 0.81
0.42
0.88
Interest Coverage No Debt
GNVC's Interest Coverage is ranked higher than
99% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GNVC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GNVC' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: 9999.99
Current: No Debt
N/A
9999.99
F-Score: 2
Z-Score: -38.86
M-Score: -1.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -742.03
GNVC's Operating margin (%) is ranked lower than
77% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. GNVC: -742.03 )
Ranked among companies with meaningful Operating margin (%) only.
GNVC' s Operating margin (%) Range Over the Past 10 Years
Min: -742.03  Med: -140.33 Max: -42
Current: -742.03
-742.03
-42
Net-margin (%) -739.55
GNVC's Net-margin (%) is ranked lower than
77% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. GNVC: -739.55 )
Ranked among companies with meaningful Net-margin (%) only.
GNVC' s Net-margin (%) Range Over the Past 10 Years
Min: -739.55  Med: -132.85 Max: -41.63
Current: -739.55
-739.55
-41.63
ROE (%) -62.55
GNVC's ROE (%) is ranked lower than
70% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. GNVC: -62.55 )
Ranked among companies with meaningful ROE (%) only.
GNVC' s ROE (%) Range Over the Past 10 Years
Min: -177.18  Med: -66.09 Max: -25.24
Current: -62.55
-177.18
-25.24
ROA (%) -52.96
GNVC's ROA (%) is ranked lower than
73% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. GNVC: -52.96 )
Ranked among companies with meaningful ROA (%) only.
GNVC' s ROA (%) Range Over the Past 10 Years
Min: -101.98  Med: -53.41 Max: -21.39
Current: -52.96
-101.98
-21.39
ROC (Joel Greenblatt) (%) -2485.62
GNVC's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. GNVC: -2485.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GNVC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2366.49  Med: -1523.24 Max: -573.01
Current: -2485.62
-2366.49
-573.01
Revenue Growth (3Y)(%) -58.10
GNVC's Revenue Growth (3Y)(%) is ranked lower than
87% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. GNVC: -58.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GNVC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -67  Med: -20.90 Max: 6
Current: -58.1
-67
6
EBITDA Growth (3Y)(%) -28.80
GNVC's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. GNVC: -28.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GNVC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -43.5  Med: -24.30 Max: 12.1
Current: -28.8
-43.5
12.1
EPS Growth (3Y)(%) -28.90
GNVC's EPS Growth (3Y)(%) is ranked lower than
77% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. GNVC: -28.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GNVC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -43.2  Med: -24.85 Max: 9.2
Current: -28.9
-43.2
9.2
» GNVC's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-08)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

GNVC Guru Trades in Q1 2015

Jim Simons 34,600 sh (+80.11%)
» More
Q2 2015

GNVC Guru Trades in Q2 2015

Jim Simons 50,300 sh (+45.38%)
» More
Q3 2015

GNVC Guru Trades in Q3 2015

Jim Simons 56,900 sh (+13.12%)
» More
Q4 2015

GNVC Guru Trades in Q4 2015

Jim Simons 65,700 sh (+15.47%)
» More
» Details

Insider Trades

Latest Guru Trades with GNVC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.55
GNVC's P/B is ranked higher than
77% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. GNVC: 1.55 )
Ranked among companies with meaningful P/B only.
GNVC' s P/B Range Over the Past 10 Years
Min: 0.43  Med: 3.51 Max: 41.64
Current: 1.55
0.43
41.64
P/S 12.77
GNVC's P/S is ranked lower than
56% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. GNVC: 12.77 )
Ranked among companies with meaningful P/S only.
GNVC' s P/S Range Over the Past 10 Years
Min: 0.62  Med: 4.88 Max: 42.41
Current: 12.77
0.62
42.41
Current Ratio 5.36
GNVC's Current Ratio is ranked higher than
55% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. GNVC: 5.36 )
Ranked among companies with meaningful Current Ratio only.
GNVC' s Current Ratio Range Over the Past 10 Years
Min: 2.21  Med: 4.46 Max: 8.13
Current: 5.36
2.21
8.13
Quick Ratio 5.36
GNVC's Quick Ratio is ranked higher than
57% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. GNVC: 5.36 )
Ranked among companies with meaningful Quick Ratio only.
GNVC' s Quick Ratio Range Over the Past 10 Years
Min: 2.21  Med: 4.46 Max: 8.13
Current: 5.36
2.21
8.13
Days Sales Outstanding 68.46
GNVC's Days Sales Outstanding is ranked lower than
52% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. GNVC: 68.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
GNVC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.64  Med: 41.81 Max: 71.17
Current: 68.46
19.64
71.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.73
GNVC's Price/Net Cash is ranked higher than
85% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: 5.42 vs. GNVC: 1.73 )
Ranked among companies with meaningful Price/Net Cash only.
GNVC' s Price/Net Cash Range Over the Past 10 Years
Min: 1.32  Med: 5.80 Max: 31.8
Current: 1.73
1.32
31.8
Price/Net Current Asset Value 1.64
GNVC's Price/Net Current Asset Value is ranked higher than
87% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. GNVC: 1.64 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GNVC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.17  Med: 5.18 Max: 18.46
Current: 1.64
1.17
18.46
Price/Tangible Book 1.53
GNVC's Price/Tangible Book is ranked higher than
82% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. GNVC: 1.53 )
Ranked among companies with meaningful Price/Tangible Book only.
GNVC' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.14  Med: 3.59 Max: 16.71
Current: 1.53
1.14
16.71
Price/Median PS Value 2.65
GNVC's Price/Median PS Value is ranked lower than
87% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. GNVC: 2.65 )
Ranked among companies with meaningful Price/Median PS Value only.
GNVC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.28  Med: 1.56 Max: 7.08
Current: 2.65
0.28
7.08
Earnings Yield (Greenblatt) (%) -199.71
GNVC's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. GNVC: -199.71 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GNVC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -199.71  Med: 413.50 Max: 16429.1
Current: -199.71
-199.71
16429.1

More Statistics

Revenue(Mil) $1
EPS $ -0.39
Beta2.79
Short Percentage of Float1.52%
52-Week Range $0.35 - 3.69
Shares Outstanding(Mil)17.26

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 1 1
EPS($) -0.30 -0.32
EPS without NRI($) -0.30 -0.32

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:PVOTF, OTCPK:BSEM, OSTO:KARE, NAS:WINT, OTCPK:EMBT, ASX:IMC » details
Traded in other countries:GVC1.Germany,
Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV. The Company is developing vaccines against RSV, the single main viral cause of lower respiratory infections in infants and young children. It is developing vaccines for the prevention and treatment of HSV including HSV type 2 the virus responsible for cases of genital herpes. With its collaborators, the Company is generating vaccine candidates for the prevention of dengue fever. Dengue fever is a viral disease spread by mosquitoes that historically affected 50 million to 100 million people each year. With its collaborators the Company is generating vaccine candidates for the prevention of malaria. With its collaborators, the Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks. FMD is a contagious viral disease affecting cows and other animals with cloven hooves. The Company currently has two suppliers for its clinical manufacturing components, one for human health and one for animal health candidates. Currently it procures raw materials, including specialized components known as resins, for its product purification and testing methods from a limited number of suppliers. The Company faces intense competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The research, development, testing, manufacture, quality, safety, effectiveness, labeling, packaging, storage, approval, distribution, marketing, advertising, and promotion of any biologic products developed by the Company or its collaborators are subject to regulation by federal, state, local, and foreign governmental authorities.
» More Articles for GNVC

Headlines

Articles On GuruFocus.com
GenVec Inc. Reports Operating Results (10-K) Mar 11 2011 
GenVec Inc. Reports Operating Results (10-Q) May 07 2010 
GenVec Inc. Reports Operating Results (10-Q) Nov 06 2009 
GenVec Inc. Reports Operating Results (10-Q) Aug 07 2009 
GenVec Inc. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
GenVec Announces $5 Million At-The-Market Offering May 05 2016
9:08 am GenVec announces 5.5 mln at the market registered direct offering of common stock with... May 05 2016
GenVec Announces $5 Million At-The-Market Offering May 05 2016
GENVEC INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 02 2016
GenVec Provides Update on Hearing Loss Clinical Program May 02 2016
GenVec Provides Update on Hearing Loss Clinical Program May 02 2016
GenVec, Inc. :GNVC-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 14 2016
GENVEC INC Financials Mar 12 2016
GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 09 2016
GenVec Reports Fourth Quarter and 2015 Year-End Financial Results Mar 09 2016
Q4 2015 GenVec Inc Earnings Release - Before Market Open Mar 09 2016
GenVec To Release Fourth Quarter And Year-End 2015 Financial Results And Conduct A Conference Call... Mar 02 2016
GENVEC INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or... Feb 26 2016
GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Jan 22 2016
GenVec Provides Investor Update Jan 20 2016
GenVec Provides Investor Update Jan 20 2016
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of GenVec, Inc. (GNVC) Jan 11 2016
GENVEC INC Files SEC form 8-K, Other Events Jan 11 2016
GenVec returns to hearing loss research with new Novartis deal Jan 07 2016
GenVec, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK